Skip to content

Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia

5-HT2A-receptor Binding: Implications for the Pathophysiology of Schizophrenia and Effects of Treatment With Antipsychotic Drugs

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00207064
Enrollment
46
Registered
2005-09-21
Start date
2004-04-30
Completion date
2008-09-30
Last updated
2011-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

first-episode, altanserin, 5-HT2A receptors, MRI, fMRI, PPI, P300, P50 gating, endophenotypes, vulnerability indicators, quetiapine

Brief summary

We want to relate disturbances in first-episode schizophrenic patients in serotonin 5-HT2A receptors, brain structure, brain function, and information processing to each other and to psychopathology. Additionally, we want to examine the influence of 5-HT2A receptor blockade on these disturbances. We expect disturbances in the serotonergic system at baseline to correlate with specific structural and functional changes and with disruption in information processing as measured with psychophysiological and neurocognitive methods - and we expect 5-HT2A receptor blockade to reverse some of the functional and cognitive impairments. We do not expect any effect of treatment on brain structure

Detailed description

Patients and matched healthy controls are examined at baseline and again after the patients have been treated for 6 months with a combined 5-HT2A- and dopamine D2- receptor blocker. We have chosen the atypical antipsychotic compound, quetiapine, for the present study since this drug is characterized by a fast koff/low affinity for the dopamine D2 receptors. The purpose of the study is to examine pathophysiological and neuropsychological mechanisms - not treatment effects. We want to characterize neurobiological and functional endophenotypes or vulnerability indicators and to study their stability over time and their relation to treatment and contemporary psychopathology. To the extent that candidate endophenotypes can be characterized as stable and independent of treatment and contemporary psychopathology they will be analysed together with similar findings from previous (identical)cohorts of schizophrenic patients. Specific disturbances will also be related to candidate genes for schizophrenia.

Interventions

DRUGquetiapine

flexible doses according to the clinical condition

Sponsors

Rigshospitalet, Denmark
CollaboratorOTHER
Copenhagen University Hospital, Hvidovre
CollaboratorOTHER
Glostrup University Hospital, Copenhagen
CollaboratorOTHER
The Danish Medical Research Council
CollaboratorOTHER
Copenhagen Hospital Corporation
CollaboratorOTHER
University of Copenhagen
CollaboratorOTHER
AstraZeneca
CollaboratorINDUSTRY
Birte Glenthoj
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* First-episode schizophrenia. The controls are matched for age, gender and parental socioeconomic status

Exclusion criteria

* Previous antipsychotic treatment, mental retardation, organic brain damage, and for the controls a psychiatric diagnosis or first-degree relatives with a psychiatric diagnosis

Design outcomes

Primary

MeasureTime frame
An extensive battery of neurocognitive measuresBaseline and after 6 months
5-HT2A receptor binding and occupancy (PET)Baseline and after 6 months
Structural MRIBaseline and after 6 months
Functional MRIBaseline and after 6 months
Information procession as measured with psychophysiological methods (P300, PPI, P50 gating ect.)Baseline and after 6 months

Secondary

MeasureTime frame
PANSSBaseline and after 6 months

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026